At a glance
ClinicalIndex Comparison RecordN/ACompleted· 89 enrolled
Drug / intervention
Molecular Breast Imagingdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Magnetic Resonance Imaging and Molecular Breast Imaging in Breast Diagnostic Evaluation
In Brief
A clinical study evaluating Molecular Breast Imaging for Breast Cancer. Completed, enrolled 89 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the sensitivity of Molecular Breast Imaging (MBI) relative to MRI of the breast in patients undergoing MRI for a clinical concern, or abnormal diagnostic mammogram and/or ultrasound study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsUnited States Department of Defense
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartSep 2008
Primary CompletionDec 2010
TodayJul 2026
First PostedJan 11, 2008
Enrollment StartSep 1, 2008
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.5 years ago
Interventions
Molecular Breast Imagingdevice
Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.